Screener
AnaptysBio, Inc. ANAB Financing Cash Flow
Financing Cash Flow at other companies
Other financials
Where this comes from
Reported directly by AnaptysBio, Inc. in its filing.
Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInFinancingActivities.
The source filing: AnaptysBio, Inc.’s 10-Q, filed May 12, 2026.
- Filed
- May 12, 2026, 4:20 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-219515
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Repurchase and retirements of common stock | — | (4,424) |
| Payment for net share settlement of equity awards | — | (1,451) |
| Principal repayment of liability for sale of future royalties | (12,812) | (23,005) |
| Net cash provided by (used in) financing activities | 1,209 | (28,590) |
| Net increase (decrease) in cash and cash equivalents | 10,273 | (24,443) |
| Cash and cash equivalents, beginning of period | 238,196 | 123,080 |
| Cash and cash equivalents, end of period | $248,469 | $98,637 |
| SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION |
Item 1. Consolidated Financial Statements
FAQ
- What is AnaptysBio, Inc.'s financing cash flow?
- AnaptysBio, Inc. (ANAB) reported financing cash flow of $1.21M in Q1 2026.
- How has AnaptysBio, Inc.'s financing cash flow changed year-over-year?
- AnaptysBio, Inc.'s financing cash flow increased by 104.2% year-over-year, from -$28.59M to $1.21M.
- What is the long-term trend for AnaptysBio, Inc.'s financing cash flow?
- Over 4 years (2021 to 2025), AnaptysBio, Inc.'s financing cash flow has grown at a -14.9% compound annual growth rate (CAGR), from $252.3M to -$132.61M.
- What does financing cash flow mean?
- Total net cash provided by or used in financing activities — debt issuance/repayment, equity transactions, and dividend payments.
Ask your AI about AnaptysBio, Inc.'s financing cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude